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ABSTRACT
Small cell neuroendocrine carcinoma rarely appears primarily in the head and neck and exhibits aggressive behavior 
with a poor prognosis. The pathologist has a significant role in the diagnosis, and a consensual treatment still does not 
exist. The authors report the case of a middle-aged male patient who presented repeated episodes of massive epistaxis. 
The diagnostic work-up disclosed the diagnosis of small cell neuroendocrine carcinoma of the nasopharynx. The patient 
was treated with chemotherapy followed by radiotherapy. Imaging examinations performed after the end of treatment 
showed apparent complete remission of the disease. The patient was kept under active surveillance with no signs of 
local relapse or distant metastasis after 4 years of follow-up. 
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INTRODUCTION
Small cel l  neuroendocrine carcinoma is a 
high-grade tumor that usually presents aggressive 
behavior. The lungs represent the most common 
primary site, and extra pulmonary cases comprise 
only 2.5–5% of the cases,1,2 mainly involving the 
esophagus,3 colon,4 urinary bladder,5 and cervix.6 
The involvement of the head and neck structures is 
even rarer, and in these cases, the larynx is the most 
frequently involved organ.7 Due to its rarity, the 
diagnosis and treatment are challenging. We present 
the case of a nasopharyngeal small cell neuroendocrine 
carcinoma, which, as far as we know, is the ninth case 
reported in the literature.8-15
CASE REPORT
A 54-year-old Caucasian male patient sought 
medical care complaining of recurrent epistaxis and 
dysphonia for 2 weeks. He had a history of heavy 
smoking. Physical examination and laboratory tests 
were normal. The computed tomography (CT) of 
the paranasal sinuses revealed the presence of an 
extensive nasopharyngeal lesion measuring 5 × 6 cm 
predominantly involving the left side, extending to 
the nasal fossae, parapharyngeal space, and pterygoid 
muscles. There was neither intracranial extension nor 
bone involvement.
A nasofibroscopy was performed showing a reddish 
lesion of the left nasal fossae, which was biopsied. 
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The result was inconclusive (esthesioneuroblastoma 
vs. small cell carcinoma), but another biopsy favored 
the diagnosis of small cell neuroendocrine carcinoma, 
confirmed by the immunohistochemical study, 
which presented diffuse expression of CAM 5.2 and 
synaptophysin in rare neoplastic cells, in the absence 
of neuron-specific enolase, chromogranin, and 
neurofilaments (Figure 1).
The magnetic resonance imaging (MRI) detected 
the infiltration of the soft palate and confirmed the 
presence of a tumor in the nasopharynx measuring 
6.5 cm at its longest axis; presenting a similar extension 
observed with the CT.
Clinical staging was II: cT2N0M0 according to 
the proposal for the 8th edition of the American Joint 
Committee on Cancer (AJCC)/Union for International 
Cancer Control (UICC).16
The patient was treated with primary chemotherapy 
with carboplatin AUC5 (day 1) and etoposide 100 mg/m2 
(days 1, 2, and 3) every 21 days. After the end of the 
fourth cycle of chemotherapy, the patient underwent 
a planning CT scan (Figure 2) and started radiotherapy 
receiving a total dose of 70 Gy to the nasopharynx and 
60 Gy to the cervical region.
On the second month of follow-up, another 
pharyngeal MRI was performed, which demonstrated 
that the pharynx was free of neoplastic lesions and no 
cervical lymph nodes were enlarged.
A CT scan of the thorax and abdomen was 
conducted on the sixth month of follow-up, which 
showed a spiculated pulmonary nodule measuring 
16 mm and another nodular lesion in the pancreatic tail, 
which were tackled by aspiration biopsy. The cytology 
was inconclusive for the pulmonary nodule, and negative 
Figure 1. Photomicrography of the biopsy specimen. A - Extensive areas of necrosis (H&E, 100X); B - Sheets of small 
cells with high nuclear-cytoplasmic ratio surrounding the vessels (H&E, 400X); C - Positivity immunostaining for CAM 
5.2 (400X); D - Focal positivity for synaptophysin (400X).
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for malignancy for the pancreatic lesion. The positron 
emission tomography using 18F-fluorodeoxyglucose 
(PET-18F-FDG) revealed the radiotracer uptake 
(SUV max = 6.96) in two lymph nodes of the pulmonary 
hilum and another in the subcarinal topography, 
besides a mild enhancement of the radiotracer uptake 
(SUV max = 2.33) in the middle pulmonary lobe, both 
suspected of metastasis. No other sites, namely the 
pancreas and the nasopharynx, showed abnormal 
radiotracer concentration consistent with a malignant 
disease. A transbronchial fine-needle aspiration of the 
hilar lymph nodes was performed by endobronchial 
ultrasound, and the cytological examination was 
negative for malignancy. Oncologic surveillance was 
maintained afterward.
DISCUSSION
T h e  n e o p l a s m s  w i t h  n e u r o e n d o c r i n e 
differentiation involving the head and neck structures, 
including the nasopharynx, are exceedingly rare. 
The diagnosis of such an entity is challenging 
because of the morphological characteristics as 
well as the biopsy sample size, which does not 
always allow the distinction among other types of 
neoplasms. The immunohistochemical study has an 
indispensable central role to confirm the epithelial and 
Figure 2. Planning CT scan showing the extensive nasopharyngeal lesion extending to the nasal fossae, parapharyngeal 
space, and pterygoid muscles, with soft palate invasion. A and B - Axial sections; C - Coronal section; D - Sagittal 
section.
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neuroendocrine nature of this kind of tumor, which 
expresses variably cytokeratins (such as CAM 5.2) 
and neuroendocrine markers like synaptophysin, 
neuron-specific enolase, chromogranin and CD56.17 
According to the WHO classification, neuroendocrine 
tumors of the nasal cavity and paranasal sinuses may be 
divided into typical carcinoid tumors, atypical carcinoid 
tumors, and small cell neuroendocrine carcinoma.18 
Recently, a new classification for neuroendocrine 
tumors of the head and neck was proposed and 
is similar to that of the lung and gastrointestinal 
tract. This classification divides these tumors into 
neuroendocrine carcinoma grade 1, grade 2, and large 
or small cell neuroendocrine carcinoma grade 3, which 
are based on the morphology, the mitotic index, and 
the presence or absence of necrosis. According to this 
classification, small cell neuroendocrine carcinomas 
present tumor cells with small size, scant cytoplasm, 
nuclei with finely granular chromatin, inconspicuous 
or absent nucleoli, a high mitotic rate, and frequent 
necrosis,19 which is in line with the case presented 
herein. The additional expression of CAM 5.2 and 
synaptophysin, confirmed by immunohistochemistry, 
endorsed the diagnosis of small cell neuroendocrine 
carcinoma. As mentioned above, the expression of 
cytokeratins and neuroendocrine markers may vary 
among tumors. In the majority of cases, the analysis 
of the other eight cases reported in the literature 
showed the expression of chromogranin,8,11,14,15 
synapthophysin,8,11,14 and CD56,11,14,15 with only one 
expressing neuron-specific enolase.8
To summarize, smal l  cel l  neuroendocrine 
carcinomas of the nasopharynx are high-grade 
tumors, and therefore convey a poor prognosis.
The therapeutic options for these tumors are 
varied. However, the treatment of choice is still 
undefined because only eight cases have been 
reported in the literature to date (Table 1).
CONCLUSION
Despite the lack of a consensual therapeutic 
modality, the multimodality approach (chemo and 
radiotherapy) showed evidence of increment in the 
survival rate of patients with the diagnosis of sinonasal 
small cell neuroendocrine carcinoma.20,21 In our case, 
the option of sequential treatment (chemo followed 
by radiotherapy) was based on the histology type and 
the tumor size. Despite the poor prognosis of this 
entity, we verified no evidence of locoregional relapse 
or distant metastasis at the end of a 4-year period of 
follow-up.
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